Sorafenib is the first-line medication for advanced hepatocellular carcinoma (HCC), but it
can only extend limited survival. It is imperative to find a combination strategy to increase …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a high
mortality rate. It is regarded as a significant public health issue because of its complicated …

Cancer cells have unlimited replicative potential, insensitivity to growth-inhibitory signals,
evasion of apoptosis, cellular stress, and sustained angiogenesis, invasiveness and …

Background: Sorafenib is the only drug approved for the treatment of hepatocellular
carcinoma (HCC). The bioenergetic propensity of cancer cells has been correlated to …

BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …

Primary liver cancer is an important cause of cancer death, and hepatocellular carcinoma
(HCC) accounts for 70%-85% of total liver cancer worldwide. Chronic hepatitis B virus (HBV) …

Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma
(HCC). The mechanism underlying this effect is not completely understood. In this work we …

Markers that could accurately predict responses to the general kinase inhibitor sorafenib are
needed to better leverage its clinical applications. In this study, we examined a hypothesized …

Sorafenib, a multikinase inhibitor, is currently the only approved drug for advanced
hepatocellular carcinoma (HCC). The current study tested the hypothesis whether inhibition …

Hepatocellular carcinoma is (HCC) the most common primary malignancy of the liver in
adults. It is also the fifth most common solid cancer worldwide and the third leading cause of …